Company profile: Storm Therapeutics
1.1 - Company Overview
Company description
- Provider of RNA-modifying enzyme–targeted therapeutics and discovery platforms, including STC-15, an oral METTL3 inhibitor for oncology; a drug discovery and RNA analytics platform to identify targets and develop small-molecule candidates for oncology, inflammation, viral infections, and CNS diseases; and a target discovery platform using chemical biology, RNA sequencing, RNA mass spectrometry, and functional genomics.
Products and services
- Drug Discovery and RNA Analytics Platform: A small-molecule-focused platform that identifies novel drug targets and architects drug candidates for oncology, inflammation, viral infections, and CNS diseases through RNA analytics
- STC-15: A mechanism-specific, oral small-molecule METTL3 inhibitor for oncology that suppresses tumor growth and activates anti-cancer immune responses by targeting RNA methyltransferase activity
- Target Discovery Platform: A multi-technique system employing chemical biology, RNA sequencing, RNA mass spectrometry, and functional genomics to pinpoint novel drug targets and rigorously validate their clinical relevance
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Storm Therapeutics
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
OncoVista Innovative Therapies
HQ: United States
Website
- Description: Provider of anticancer therapy development utilizing tumor-associated biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoVista Innovative Therapies company profile →
Oncoscope
HQ: United States
Website
- Description: Provider of optical biopsy and imaging systems for epithelial tissues in the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder, delivering in vivo measurements of cell nuclei diameter and density to help physicians identify pre-cancerous tissues for biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoscope company profile →
OncoEthix
HQ: Switzerland
Website
- Description: Provider of cancer drug development, advancing a portfolio of three to five promising oncology compounds through clinical development; a private Swiss company founded in 2007.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoEthix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Storm Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Storm Therapeutics
2.2 - Growth funds investing in similar companies to Storm Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Storm Therapeutics
4.2 - Public trading comparable groups for Storm Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →